HIV-1 Protease with 20 Mutations Exhibits Extreme Resistance to Clinical Inhibitors through Coordinated Structural Rearrangements
- 10 March 2012
- journal article
- research article
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 51 (13), 2819-2828
- https://doi.org/10.1021/bi2018317
Abstract
No abstract availableKeywords
This publication has 50 references indexed in Scilit:
- Critical differences in HIV‐1 and HIV‐2 protease specificity for clinical inhibitorsProtein Science, 2012
- The higher barrier of darunavir and tipranavir resistance for HIV-1 proteaseBiochemical and Biophysical Research Communications, 2011
- The L76V Drug Resistance Mutation Decreases the Dimer Stability and Rate of Autoprocessing of HIV-1 Protease by Reducing Internal Hydrophobic ContactsBiochemistry, 2011
- Probing Multidrug‐Resistance and Protein–Ligand Interactions with Oxatricyclic Designed Ligands in HIV‐1 Protease InhibitorsChemMedChem, 2010
- Autocatalytic maturation, physical/chemical properties, and crystal structure of group N HIV‐1 protease: Relevance to drug resistanceProtein Science, 2010
- Subtype Polymorphisms Among HIV-1 Protease Variants Confer Altered Flap Conformations and FlexibilityJournal of the American Chemical Society, 2009
- Interactions of different inhibitors with active‐site aspartyl residues of HIV‐1 protease and possible relevance to pepsinProteins-Structure Function and Bioinformatics, 2008
- Ultra-high Resolution Crystal Structure of HIV-1 Protease Mutant Reveals Two Binding Sites for Clinical Inhibitor TMC114Journal of Molecular Biology, 2006
- [20] Processing of X-ray diffraction data collected in oscillation modeMethods in Enzymology, 1997
- Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infectionNature, 1995